Calliditas patents expiration
1. Tarpeyo patents expiration
TARPEYO's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8491932 | CALLIDITAS | Compositions for the oral delivery of corticosteroids |
May, 2029
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Dec 15, 2028 |
| New Product (NP) | Dec 15, 2024 |
Drugs and Companies using BUDESONIDE ingredient
Market Authorisation Date: 15 December, 2021
Treatment: Treatment of primary immunoglobulin a nephropathy (igan) in adults at risk of rapid disease progression
Dosage: CAPSULE, DELAYED RELEASE;ORAL
More Information on Dosage
TARPEYO family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic